SCHEMBL7218239

SCHEMBL7218239

CCN(CC)CCn1ccc(NC(=O)c2c[nH]c3c2-c2ncccc2CCC3)n1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCK P35557 2/20 0.33
NPSR1 Q6W5P4 1/20 0.33
PDE4B Q07343 1/20 0.32
PDE4D Q08499 1/20 0.32
KDM4E B2RXH2 2/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
LMNA P02545 1/20 0.31
CHRM2 P08172 1/20 0.30
CHRM4 P08173 1/20 0.30
CHRM1 P11229 1/20 0.30
CHRM3 P20309 1/20 0.30
NPC1 O15118 1/20 0.30
GAA P10253 1/20 0.30
RAB9A P51151 1/20 0.30
GRM5 P41594 1/20 0.30
EGFR P00533 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
MEN1 O00255 1/20 0.30
CCR6 P51684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7223491 0.95 GCK (0.32) GCKNPSR1PDE4BPDE4DKDM4E
SCHEMBL7222958 0.89 NPSR1 (0.34) GCKNPSR1PDE4BPDE4DKDM4E
SCHEMBL7223214 0.88 NPSR1 (0.34) GCKNPSR1PDE4BPDE4DKDM4E
SCHEMBL7218258 0.87 GCK (0.33) GCKNPSR1PDE4BPDE4DLMNA
SCHEMBL7222707 0.87 GCK (0.34) GCKNPSR1PDE4BPDE4DKDM4E
SCHEMBL7217066 0.86 GCK (0.40) GCKNPSR1CHRM2CHRM4CHRM1
SCHEMBL7218419 0.86 GCK (0.40) GCKNPSR1CHRM2CHRM4CHRM1
SCHEMBL7221707 0.86 GCK (0.32) GCKNPSR1
SCHEMBL7218337 0.85 GCK (0.33) GCKNPSR1PDE4BPDE4DKDM4E
SCHEMBL7223026 0.85 GCK (0.33) GCKNPSR1PDE4BPDE4DLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 US disclosed